Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal? Hannah R. WardillJoanne M. BowenRachel J. Gibson Review Article 30 September 2012 Pages: 627 - 635
PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy Y. Z. ChenJ. Y. XueJ. Wu Original Article 19 August 2012 Pages: 637 - 644
Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer Minoru FukudaYoichi NakamuraShigeru Kohno Original Article 22 August 2012 Pages: 645 - 651
Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors Anne-Charlotte DubbelmanAlana UpthagroveJan H. M. Schellens Original Article 22 August 2012 Pages: 653 - 663
A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02 Yoon Hee ChoiSang Cheul OhHye Jin Kang Original Article 25 August 2012 Pages: 665 - 672
A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors R. SalazarR. J. JonesT. R. J. Evans Original Article 25 August 2012 Pages: 673 - 681
A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer Hyun-Jeong ShimDae-Eun KimIk-Joo Chung Original Article 30 August 2012 Pages: 683 - 690
Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer Hiroki GoyaHiroshi KuraishiTomonobu Koizumi Original Article 01 September 2012 Pages: 691 - 697
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors Jeffrey R. InfanteVicki L. KeedyHoward A. Burris III Original Article 02 September 2012 Pages: 699 - 705
Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors Song DongXu-Chao ZhangYi-Long Wu Original Article 02 September 2012 Pages: 707 - 716
Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity N. ChenC. KasserraH. Lau Original Article 06 September 2012 Pages: 717 - 725
Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer Colm FarrellCharles SchweizerMartin D. Phillips Original Article Open access 07 September 2012 Pages: 727 - 734
Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy Byung Woog KangJi Yun JeongJong Gwang Kim Original Article 07 September 2012 Pages: 735 - 741
A biomarker profile for predicting efficacy of cisplatin–vinorelbine therapy in malignant pleural mesothelioma Zarah Glad ZimlingJens Benn SørensenEric Santoni-Rugiu Original Article 08 September 2012 Pages: 743 - 754
Phase I trial of pomalidomide given for patients with advanced solid tumors Matthew M. CooneyCharles NockAfshin Dowlati Clinical Trial Report 09 August 2012 Pages: 755 - 761
Erratum to: The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response Trevor G. GlarosLuke H. StockwinDianne L. Newton Erratum 30 September 2012 Pages: 763 - 764
